The old rules no longer apply. In today’s complex and competitive pharma environment, drug developers who rely on fragmented outsourcing models risk falling behind. Spreading critical functions across multiple vendors may seem flexible—but this can often lead to operational inefficiencies, delayed timelines, and increased risk.
This white paper challenges conventional thinking and presents a smarter, more strategic approach—one embodied by Accelerator™ Drug Development, Thermo Fisher Scientific’s CDMO and CRO solutions. By consolidating development and manufacturing within a connected partnership, biotech and biopharma companies can:
Explore how redefining value—beyond just cost and speed—can position your program for long-term success.